KALA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
KALA BIO, INC. (KALA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $3.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-03-03
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $3.00K, a 99.26% decline from fiscal 2021.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $406.00K, a 80.89% decline from fiscal 2020.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.12M, a 2067.35% increase from fiscal 2019.
- KALA BIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $98.00K, a 92.46% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|
| 2022-12-31 | $3.00K 10-K · filed 2023-03-03 | |
| 2021-12-31 | $406.00K 10-K · filed 2023-03-03 | |
| 2020-12-31 | $2.12M 10-K · filed 2022-03-29 | |
| 2019-12-31 | $98.00K 10-K · filed 2021-02-25 | $100.00K 10-K · filed 2020-02-12 |
| 2018-12-31 | $1.30M 10-K · filed 2020-02-12 | |
| 2017-12-31 | $4.70M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $0.00 10-K · filed 2018-04-02 | |
| 2015-12-31 | $552.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |